Modulating P1 Adenosine Receptors in Disease Progression of SOD1
Adenosine
/ analogs & derivatives
Amyotrophic Lateral Sclerosis
/ drug therapy
Animals
Disease Models, Animal
Mice, Transgenic
Microglia
/ drug effects
Motor Neurons
/ drug effects
Phenethylamines
/ pharmacology
Receptors, Purinergic P1
/ drug effects
Spinal Cord
/ drug effects
Superoxide Dismutase-1
/ drug effects
Adenosine A1 receptors (A1Rs)
Adenosine A2A receptors (A2ARs)
Amyotrophic lateral sclerosis (ALS)
SOD1G93A mice
Journal
Neurochemical research
ISSN: 1573-6903
Titre abrégé: Neurochem Res
Pays: United States
ID NLM: 7613461
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
04
10
2018
accepted:
30
01
2019
revised:
30
01
2019
pubmed:
14
2
2019
medline:
14
6
2019
entrez:
14
2
2019
Statut:
ppublish
Résumé
Amyotrophic lateral sclerosis (ALS) is a fatal progressing neurodegenerative disease; to date, despite the intense research effort, only two therapeutic options, with very limited effects, are available. The purinergic system has been indicated as a possible new therapeutic target for ALS, but the results are often contradictory and generally confused. The present study was designed to determine whether P1 adenosine receptor ligands affected disease progression in a transgenic model of ALS. SOD1
Identifiants
pubmed: 30756215
doi: 10.1007/s11064-019-02745-0
pii: 10.1007/s11064-019-02745-0
doi:
Substances chimiques
Phenethylamines
0
Receptors, Purinergic P1
0
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine
120225-54-9
Sod1 protein, mouse
EC 1.15.1.1
Superoxide Dismutase-1
EC 1.15.1.1
Adenosine
K72T3FS567
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1037-1042Références
Beghi E, Pupillo E, Messina P, Giussani G, Chiò A, Zoccolella S et al (2011) Coffee and amyotrophic lateral sclerosis: a possible preventive role. Am J Epidemiol 174:1002–1008
doi: 10.1093/aje/kwr229
pubmed: 21946385
Fondell E, O’Reilly ÉI, Fitzgerald KC, Falcone GJ, Kolonel LN, Park Y et al (2015) Intakes of caffeine, coffee and tea and risk of amyotrophic lateral sclerosis: Results from five cohort studies. Amyotroph Lateral Scler Frontotemporal Degener 16(5–6):366–371
doi: 10.3109/21678421.2015.1020813
pubmed: 25822002
pmcid: 4589421
Pupillo E, Bianchi E, Chiò A, Casale F, Zecca C, Tortelli R et al (2018) Amyotrophic lateral sclerosis and food intake. Amyotroph Lateral Scler Frontotemporal Degener 19(3–4):267–274
doi: 10.1080/21678421.2017.1418002
pubmed: 29268633
Potenza RL, Armida M, Ferrante A, Pèzzola A, Matteucci A, Puopolo M, Popoli P (2013) Effects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosis. J Neurosci Res 91(4):585–592
doi: 10.1002/jnr.23185
pubmed: 23361938
Yanpallewar SU, Barrick CA, Buckley H, Becker J, Tessarollo L (2012) Deletion of the BDNF truncated receptor TrkB.T1 delays disease onset in a mouse model of amyotrophic lateral sclerosis. PLoS ONE 7:e39946
doi: 10.1371/journal.pone.0039946
pubmed: 22761934
pmcid: 3384607
Ng SK, Higashimori H, Tolman M, Yang Y (2015) Suppression of adenosine 2a receptor (A2aR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 267:115–122
doi: 10.1016/j.expneurol.2015.03.004
pubmed: 25779930
pmcid: 5363273
Nascimento F, Sebastião AM, Ribeiro JA (2015) Presymptomatic and symptomatic ALS SOD1 (G93A) mice differ in adenosine A1 and A2A receptor-mediated tonic modulation of neuromuscular transmission. Purinergic Signal 11(4):471–480
doi: 10.1007/s11302-015-9465-4
pubmed: 26335190
pmcid: 4648802
Martire A, Calamandrei G, Felici F, Scattoni ML, Lastoria G, Domenici MR, Tebano MT, Popoli P (2007) Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington’s disease versus wild-type mice. Neurosci Lett 417(1):78–83
doi: 10.1016/j.neulet.2007.02.034
pubmed: 17331645
Ferrante A, Martire A, Armida M, Chiodi V, Pézzola A, Potenza RL, Domenici MR, Popoli P (2010) Influence of CGS 21680, a selective adenosine A(2A) receptor agonist, on NMDA receptor function and expression in the brain of Huntington’s disease mice. Brain Res 1323:184–191
doi: 10.1016/j.brainres.2010.01.080
pubmed: 20138162
Chou SY, Lee YC, Chen HM, Chiang MC, Lai HL, Chang HH, Wu YC, Sun CN, Chien CL, Lin YS, Wang SC, Tung YY, Chang C, Chern Y (2005) CGS21680 attenuates symptoms of Huntington’s disease in a transgenic mouse model. J Neurochem 93(2):310–320
doi: 10.1111/j.1471-4159.2005.03029.x
pubmed: 15816854
Hockemeyer J, Burbiel JC, Müller CE (2004) Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson’s disease. J Org Chem 69(10):3308–3318
doi: 10.1021/jo0358574
pubmed: 15132536
Ludolph AC, Bendotti C, Blaugrund E et al (2010) Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler 11:38–45
doi: 10.3109/17482960903545334
pubmed: 20184514
Nagel J, Schladebach H, Koch M, Schwienbacher I, Müller CE, Hauber W (2003) Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats. Synapse 49(4):279–286
doi: 10.1002/syn.10240
pubmed: 12827647
Mingote S, Pereira M, Farrar AM, McLaughlin PJ, Salamone JD (2008) Systemic administration of the adenosine A(2A) agonist CGS 21680 induces sedation at doses that suppress lever pressing and food intake. Pharmacol Biochem Behav 89:345–351
doi: 10.1016/j.pbb.2008.01.006
pubmed: 18281083
pmcid: 2674372
Gnad T, Scheibler S, von Kügelgen I, Scheele C, Kilić A, Glöde A, Hoffmann LS, Reverte-Salisa L, Horn P, Mutlu S, El-Tayeb A, Kranz M, Deuther-Conrad W, Brust P, Lidell ME, Betz MJ, Enerbäck S, Ju¨rgen Schrader J, Yegutkin GG, Müller CE, Pfeifer A (2014) Adenosine activates brown adipose tissue and recruits beige adipocytes via A2A receptors. Nature 516(7531):395–399
doi: 10.1038/nature13816
pubmed: 25317558
DeOliveira CC, Paiva Caria CR, Ferreira Gotardo EM, Ribeiro ML, Gambero A (2017) Role of A1 and A2A adenosine receptor agonists in adipose tissue inflammation induced by obesity in mice. Eur J Pharmacol 799:154–159
doi: 10.1016/j.ejphar.2017.02.017
pubmed: 28202393
Klaasse EC, Ljzerman AP, de Grip WJ, Beukers MW (2008) Internalization and desensitization of adenosine receptors. Purinergic Signal 4(1):21–37
doi: 10.1007/s11302-007-9086-7
pubmed: 18368531
Vincenzi F, Corciulo C, Targa M, Casetta I, Gentile M, Granieri E, Borea PA, Popoli P, Varani K (2013) A2A adenosine receptors are up-regulated in lymphocytes from amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 14(5–6):406–413
doi: 10.3109/21678421.2013.793358
pubmed: 23679925
Chen JF, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, Geiger J, Lopes LV, de Mendonça A (2007) Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulation. Prog Neurobiol 83(5):310–331
doi: 10.1016/j.pneurobio.2007.09.002
pubmed: 18023959
Popoli P, Blum D, Martire A, Ledent C, Ceruti S, Abbracchio MP (2007) Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington’s disease. Prog Neurobiol 81(5–6):331–348
doi: 10.1016/j.pneurobio.2006.12.005
pubmed: 17303312
Popoli P (2008) Regulation of brain functions by A2A receptors: implication for therapeutics. Curr Pharm Des 14(15):1466–1467
doi: 10.2174/138161208784480135
pubmed: 18537669
Laurent C, Burnouf S, Ferry B, Batalha VL, Coelho JE, Baqi Y, Malik E, Mariciniak E, Parrot S, Van der Jeugd A, Faivre E, Flaten V, Ledent C, D’Hooge R, Sergeant N, Hamdane M, Humez S, Müller CE, Lopes LV, Buée L, Blum D (2016) A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Mol Psychiatry 21(1):97–107
doi: 10.1038/mp.2014.151
pubmed: 25450226
Nascimento F, Pousinha PA, Correia AM, Gomes R, Sebastião AM, Ribeiro JA (2014) Adenosine A2A receptors activation facilitates neuromuscular transmission in the pre-symptomatic phase of the SOD1 (G93A) ALS mice, but not in the symptomatic phase. PLoS ONE 9(8):e104081
doi: 10.1371/journal.pone.0104081
pubmed: 25093813
pmcid: 4122437
Sebastião AM, Rei N, Ribeiro JA (2018) Amyotrophic lateral sclerosis (ALS) and adenosine receptors. Front Pharmacol 9:267
doi: 10.3389/fphar.2018.00267
pubmed: 29713276
pmcid: 5911503
Pedata F, Dettori I, Coppi E, Melani A, Fusco I, Corradetti R, Pugliese AM (2016) Purinergic signalling in brain ischemia. Neuropharmacology 104:105–130
doi: 10.1016/j.neuropharm.2015.11.007
pubmed: 26581499
Popoli P, Minghetti L, Tebano MT, Pintor A, Domenici MR, Massotti M (2004) Adenosine A2A receptor antagonism and neuroprotection: mechanisms, lights, and shadows. Crit Rev Neurobiol 16(1–2):99–106
doi: 10.1615/CritRevNeurobiol.v16.i12.110
pubmed: 15581405
Conlay LA, Conant JA, deBros F, Wurtman R (1997) Caffeine alters plasma adenosine levels. Nature 389(6647):136
doi: 10.1038/38160
pubmed: 9296490
Ciruela F, Casadó V, Rodrigues RJ, Luján R, Burgueño J, Canals M, Borycz J, Rebola N, Goldberg SR, Mallol J, Cortés A, Canela EI, López-Giménez JF, Milligan G, Lluis C, Cunha RA, Ferré S, Franco R (2006) Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci 26(7):2080–2087
doi: 10.1523/JNEUROSCI.3574-05.2006
pubmed: 16481441
pmcid: 6674939
Ferré S, Ciruela F, Borycz J, Solinas M, Quarta D, Antoniou K, Quiroz C, Justinova Z, Lluis C, Franco R, Goldberg SR (2008) Adenosine A1-A2 receptor heteromers: new targets for caffeine in the brain. Front Biosci 13:2391–2399
doi: 10.2741/2852
pubmed: 17981720